Vimarsana
Biggest News Aggregation in the World

Page 6 - Updated Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Updated Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Updated Phase Today - Breaking & Trending Today

Lithium Miners News For The Month Of April 2022 - Vimarsana News

Lithium Miners News For The Month Of April 2022

Lithium prices were slightly down the past month. Click here to read more about Lithium market news and Lithium company news.

SIGMA LITHIUM UPDATES FEASIBILITY STUDY WITH PHASE 1 AFTER-TAX NPV OF US$1.6 BN, INCREASING MINERAL RESERVES 2.6x TO 34MT AND SUPPORTING PHASE 1 AND PHASE 2 COMBINED POTENTIAL PRODUCTION CAPACITY ... - Vimarsana News

SIGMA LITHIUM UPDATES FEASIBILITY STUDY WITH PHASE 1 AFTER-TAX NPV OF US$1.6 BN, INCREASING MINERAL RESERVES 2.6x TO 34MT AND SUPPORTING PHASE 1 AND PHASE 2 COMBINED POTENTIAL PRODUCTION CAPACITY ...

PLANNED PHASE 1 PRODUCTION AND ESTIMATED PHASE 2 SCALE UPUpdated Phase 1 Feasibility Study base case to produce 230,000 tpa (34,000 LCE) of 6% Bat...

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021 - Vimarsana News

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral...

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021 - Vimarsana News

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral...

Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy - Vimarsana News

Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for...